Doctors often mix antibiotics to fight tough infections like MRSA. But does the lab test prove the mix will work in a person? A new look at patient data suggests the answer might be yes for some cases. Researchers analyzed results from 150 adults with MRSA bloodstream infections. They compared patients whose drug combinations showed strong lab activity against those with weak lab activity. The main question was whether this lab signal predicted better survival.
The group with strong lab activity saw a significant drop in deaths within 14 days. Only three patients died in this group compared to nearly thirteen in the other group. However, the overall death rate at 90 days was similar for both groups. The team also found that infections cleared slightly slower in the strong lab activity group, though this difference was not statistically significant.
This analysis was not a new trial but a review of existing data. The researchers call these results hypothesis generating. They warn that positive lab results do not guarantee success for every patient. Combination therapy may be beneficial when positive interactions are present, but it is not universally effective. Future randomized trials are needed to confirm if testing lab interactions can truly guide better treatment choices.